Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-11-08 00:00:00 ET · period of report 2023-11-07 · accession 0001968202-23-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-08 | 2023-11-07 | REGN | RYAN ARTHUR F | Dir | S - Sale | $827.90 | -100 | 18.6K | -0.5% | -$82.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-07 | S | D | 11 | $827.65 | 18,608 | D | — | — | (F5) Represents volume-weighted average price of sales of 11 shares of Company stock on November 7, 2023 at prices ranging from $827.03 to $827.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 2 | Common | Common Stock | 2023-11-07 | S | D | 18 | $829.43 | 18,551 | D | — | — | (F7) Represents volume-weighted average price of sales of 18 shares of Company stock on November 7, 2023 at prices ranging from $829.10 to $829.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 3 | Common | Common Stock | 2023-11-07 | S | D | 3 | $830.39 | 18,548 | D | — | — | (F8) Represents volume-weighted average price of sales of 3 shares of Company stock on November 7, 2023 at prices ranging from $830.04 to $830.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 4 | Common | Common Stock | 2023-11-07 | S | D | 1 | $838.46 | 18,547 | D | — | — | |
| 5 | Common | Common Stock | 2023-11-07 | S | D | 4 | $826.58 | 18,619 | D | — | — | (F4) Represents volume-weighted average price of sales of 4 shares of Company stock on November 7, 2023 at prices ranging from $826.44 to $826.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 6 | Common | Common Stock | 2023-11-07 | S | D | 18 | $825.53 | 18,623 | D | — | — | (F3) Represents volume-weighted average price of sales of 18 shares of Company stock on November 7, 2023 at prices ranging from $825.04 to $825.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 7 | Common | Common Stock | 2023-11-07 | S | D | 6 | $824.59 | 18,641 | D | — | — | (F2) Represents volume-weighted average price of sales of 6 shares of Company stock on November 7, 2023 at prices ranging from $824.14 to $824.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |
| 8 | Common | Common Stock | 2023-11-07 | S | D | 39 | $828.54 | 18,569 | D | — | — | (F6) Represents volume-weighted average price of sales of 39 shares of Company stock on November 7, 2023 at prices ranging from $828.01 to $828.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. |